Recurrent transient visual loss in secretory carcinoid tumor
Clinicians should be aware that TVL can be a manifestation of the vasoactive secretory products in patients with history of carcinoid tumor.
Authors
- Noor Laylani (ORCID: https://orcid.org/0000-0002-6049-0764)
- Pamela Davila-Siliezar
- Vivian Paraskevi Douglas (ORCID: https://orcid.org/0000-0002-5300-5468)
- Yingchao Piao
- Shahin Owji
- Chaow Charoenkijkajorn (ORCID: https://orcid.org/0000-0002-3563-8448)
- Mohammad Pakravan
- Andrew G. Lee (ORCID: https://orcid.org/0000-0002-5899-2239)
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Cornell University (US)
- University of Iowa Hospitals and Clinics (US)
- Methodist Hospital (US)
- Weill Cornell Medicine (US)
- The University of Texas Medical Branch at Galveston (US)
- Bryan College (US)
Publication Details
- Journal
- American Journal of Ophthalmology Case Reports
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1016/j.ajoc.2025.102289
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00